The results of a late-stage trial show Menveo could offer protection against meningitis — an infection of the brain and spinal cord. Now, the drugmaker intends to file Menveo for use in infants in the U.S. and Europe.
Continue reading Novartis’s Vaccine Menveo Meets Goals in Protecting Infants From Meningitis
Novartis’s Vaccine Menveo Meets Goals in Protecting Infants From Meningitis originally appeared on DailyFinance on Mon, 25 Oct 2010 12:05:00.
Filed Under: Company News, Health Care, Novartis, Stocks in the News